HDT Bio has been awarded a nearly USD 1.8 million grant from the U.S. Army Medical Research Acquisition Activity to develop HDT-201 into an antiviral intranasal spray that can stimulate the body's innate immune system to treat and prevent a broad spectrum of deadly human viruses.
SymBio Pharmaceuticals has entered into a collaboration agreement with the National Institute of Neurological Disorders and Stroke (NINDS) on the evaluation of brincidofovir's potential antiviral effect on Epstein Barr virus (EBV).
Infex Therapeutics has been awarded a grant of GBP 850,000 by Innovate UK Biomedical Catalyst to support its 18-month COV-X project, currently in the preclinical phase, on the optimization of a novel series of SARS-CoV-2 inhibitors.
Shanghai Shengdi Pharmaceutical, Shanghai Senhui Pharmaceutical and Jiangsu Hengrun Pharmaceutical have divulged new cephems (cephalosporins) reported to be useful for the treatment of Gram-negative bacterial infections.
Innovation Pharmaceuticals' brilacidin, a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.
Several hepatitis A outbreaks have occurred in recent years. Although vaccines exist, effective antivirals against hepatitis A virus (HAV) are lacking, and knowledge gaps remain regarding the viral replication cycle.
Now that the U.S. Department of Health and Human Services (HHS) has declared monkeypox a public health emergency, nearly two weeks after a similar declaration from the World Health Organization, the way is cleared for a coordinated response and emergency use authorizations to address supply challenges that could limit the availability of currently approved vaccines. It also has several companies ready to leap into the fray if their preclinical studies show a path to approval. HHS said it just shipped more than 602,000 doses of the Jynneos vaccine to states and jurisdictions, an increase of 266,000 in the past week.
F2G Ltd. has raised a further $70 million in venture capital as it continues preparations to submit a new drug application to the U.S. FDA for its novel antifungal drug, olorofim, before the end of 2022.
Yale University has presented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
RSS
